Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells.


Journal

Bioorganic chemistry
ISSN: 1090-2120
Titre abrégé: Bioorg Chem
Pays: United States
ID NLM: 1303703

Informations de publication

Date de publication:
10 2019
Historique:
received: 04 04 2019
revised: 09 07 2019
accepted: 11 07 2019
pubmed: 28 7 2019
medline: 22 10 2020
entrez: 27 7 2019
Statut: ppublish

Résumé

The study is focused on the design and synthesis of amide tethered quinoline-resorcinol hybrid constructs as a new class of HSP90 inhibitor. In-vitro studies of the synthetic compounds led to the identification of compound 11, which possesses potent cell growth inhibitory effects against HCT116, Hep3B and PC-3 cell lines, exerted through HSP90 inhibition. Compound 11 triggers degradation of HSP90 client proteins along with concomitant induction of HSP70, demonstrates apoptosis inducing ability and causes G2M phase cell cycle arrest in PC-3 cells. Molecular modeling was used to dock compound 11 into the HSP90 active site and key interactions with the amino acid residues of the HSP90 chaperone protein were determined.

Identifiants

pubmed: 31349117
pii: S0045-2068(19)30530-9
doi: 10.1016/j.bioorg.2019.103119
pii:
doi:

Substances chimiques

Amides 0
Antineoplastic Agents 0
HSP90 Heat-Shock Proteins 0
Quinolines 0
Resorcinols 0
quinoline E66400VT9R
resorcinol YUL4LO94HK

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

103119

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

Kunal Nepali (K)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.

Mei-Hsiang Lin (MH)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.

Min-Wu Chao (MW)

The Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Sheng-Jhih Peng (SJ)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan.

Kai-Cheng Hsu (KC)

The Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; TMU Biomedical Commercialization Center, Taiwan.

Tony Eight Lin (T)

The Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.

Mei-Chuan Chen (MC)

Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taiwan.

Mei-Jung Lai (MJ)

TMU Biomedical Commercialization Center, Taiwan.

Shiow-Lin Pan (SL)

The Ph.D. Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan; TMU Biomedical Commercialization Center, Taiwan.

Jing-Ping Liou (JP)

School of Pharmacy, College of Pharmacy, Taipei Medical University, Taiwan; Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taiwan; TMU Biomedical Commercialization Center, Taiwan; School of Pharmacy, National Defense Medical Center, Taipei, Taiwan. Electronic address: jpl@tmu.edu.tw.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH